Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens

Front Oncol. 2021 Apr 14:11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021.

¹ Hematology Unit, "Annunziata" Hospital of Cosenza, Cosenza, Italy.
² Division of Hematology, AOU Policlinico, Catania, Italy.
³ Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy.
⁴ Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
⁵ Hematology and Bone Marrow Transplant Unit, Hemato-Oncology Department, Augusta Victoria Hospital, East Jerusalem, Israel.

No abstract available

Keywords: bortezomib; carfilzomib; daratumumab; isatuximab; lenalidomide; myeloma; network meta analysis.